Trial Profile
The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2023
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
- Indications Hypoglycaemia; Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms HypoDeg
- 06 Oct 2023 Primary endpoint (Symptomatic nocturnal hypoglycaemia) has been met, as per results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 06 Oct 2023 Results assessing the proportion of participants to whom the overall result is applicable to analyzed data from the HypoDeg trial on hypoglycaemia and HbA1c outcomes at a single-patient level, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Sep 2022 Results (n=149) of substudy comparing treatment with IDeg or IGla in patients with T1D and at least one nocturnal severe hypoglycaemic event within thelast two years presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.